Viewing Study NCT06525220


Ignite Creation Date: 2025-12-25 @ 4:14 AM
Ignite Modification Date: 2026-01-10 @ 12:41 PM
Study NCT ID: NCT06525220
Status: RECRUITING
Last Update Posted: 2025-12-19
First Post: 2024-07-24
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
Sponsor: Merus N.V.
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module